Allinaire Therapeutics

Allinaire Therapeutics, LLC is a biotechnology company based in Cleveland, Ohio, founded in 2015. The company focuses on developing innovative therapeutics for chronic obstructive pulmonary disease (COPD) and other pulmonary diseases. Its research is grounded in the discovery of a novel therapeutic target identified by its scientific founders, Irina Petrache, MD, and Matthias Clauss, Ph.D. This target is significant in the understanding and treatment of lung diseases, including pulmonary arterial hypertension (PAH). By targeting this mechanism, Allinaire Therapeutics aims to provide new treatment options that could improve clinical outcomes for patients suffering from various cardiopulmonary conditions.